Table 1.
Patient baseline demographic and clinical characteristics
| Covariate | Infants < 2 years n = 2 | Children 2 to < 12 years n = 29 | Adolescents 12 to < 18 years n = 38 | Young adults ≥ 18 years n = 18 | ||||
|---|---|---|---|---|---|---|---|---|
| n (%) | Median (min–max) | n (%) | Median (min–max) | n (%) | Median (min–max) | n (%) | Median (min–max) | |
| Age, years | 2 | 1 (0.6–1.5) | 29 | 7 (2–11) | 38 | 15 (12–17) | 18 | 22 (18–29) |
| Body weight, kg | 2 | 9.1 (8.7–9.5) | 29 | 22.5 (12.0–74.4) | 38 | 51.1 (28.2–105) | 18 | 61.0 (46.2–154) |
| Albumin, g/L | 2 | 33 (30–35) | 28a | 41 (23–46) | 38 | 41 (29–49) | 18 | 39 (27–47) |
| Tumor burden, mm | 2 | 59 (35–83) | 23b | 55 (15–301) | 28d | 78 (11–208) | 15e | 120 (10–258) |
| Female | 1 (50) | – | 14 (48) | – | 16 (42) | – | 9 (50) | – |
| ADA positive | 0 (0)a | – | 5 (17)c | – | 4 (11)e | – | 2 (11)a | – |
| No. of tumor types present | 2 | 1 | 29 | 12 | 38 | 15 | 18 | 10 |
| Lansky/Karnofsky PS | 2 | 90 (90–90) | 29 | 100 (60–100) | 38 | 90 (70–100) | 18 | 95 (70–100) |
Abbreviations: ADA Anti-drug antibodies, PS Performance status
an = 1, bn = 6, cn = 5, dn = 10, en = 3 missing covariates were imputed to the median value